D-Serine
10 benefits mapped to clinical evidence across supplements.
Benefit Evidence
Research sources
Learning (5)
- Association between increased serum d-serine and cognitive gains induced by intensive cognitive training in schizophrenia
PubMed ID: 29699895
Increases in serum Dāserine during auditory training correlated strongly with verbal learning gains (associational evidence linking Dāserine to learning).
- Behavioral and cognitive effects of the N-methyl-D-aspartate receptor co-agonist D-serine in healthy humans: initial findings
PubMed ID: 25554623
Acute Dāserine improved verbal memory resistance to interference (RAVLT list 7), a learningārelated outcome.
- Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine
PubMed ID: 27913408
Repeated Dāserine improved auditory learning and related EEG measures in schizophrenia (direct learning outcome with biomarker support).
- The effect of D-serine administration on cognition and mood in older adults
PubMed ID: 26933803
Singleādose Dāserine in older adults reduced Groton Maze legal errors (spatial/executive measure) significantly (direct executive benefit).
- Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine
PubMed ID: 36958998
Weekly Dāserine combined with auditory training improved auditory learning in a doseādependent manner (direct evidence).
Brain health (4)
- Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine
PubMed ID: 36958998
Doseādependent auditory plasticity with dāserine + training suggests potential for sustaining brain function over time, though longāterm outcomes not tested.
- The effect of D-serine administration on cognition and mood in older adults
PubMed ID: 26933803
Single oral dāserine in older adults produced a modest but significant improvement on a spatial learning/executive test (direct olderāadult evidence).
- Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine
PubMed ID: 27913408
Repeated dāserine produced durable auditory plasticity and biomarker changes, suggestive of mechanisms relevant to longāterm brain health.
- Association between increased serum d-serine and cognitive gains induced by intensive cognitive training in schizophrenia
PubMed ID: 29699895
Correlations between endogenous Dāserine changes and cognitive gains during training imply a role in experienceādependent brain maintenance.
Nerve health (4)
- Association between increased serum d-serine and cognitive gains induced by intensive cognitive training in schizophrenia
PubMed ID: 29699895
Correlations between Ī Dāserine and trainingārelated cognitive gains support Dāserine's role in experienceādependent plasticity.
- Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine
PubMed ID: 27913408
Repeated Dāserine improved auditory plasticity and EEG indices (Īø response, MMN) ā strong direct evidence of enhanced neuroplasticity.
- Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine
PubMed ID: 36958998
Doseādependent auditory training + dāserine produced sustained plasticity improvements (direct, translational evidence).
- The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial
PubMed ID: 36928351
DAAO inhibitor raising Dāserine improved MMN at low dose, consistent with facilitating NMDARādependent plasticity (small study).
Ear health (3)
- Dose-Dependent Augmentation of Neuroplasticity-Based Auditory Learning in Schizophrenia: A Double-Blind, Placebo-Controlled, Randomized, Target Engagement Clinical Trial of the NMDA Glutamate Receptor Agonist d-serine
PubMed ID: 36958998
Weekly dāserine combined with auditory training improved auditory learning and produced EEG changes at mid/high doses.
- Neurophysiological mechanisms of cortical plasticity impairments in schizophrenia and modulation by the NMDA receptor agonist D-serine
PubMed ID: 27913408
Repeated dāserine improved auditory plasticity and mismatch negativity in schizophrenia (direct auditory processing improvements).
- The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial
PubMed ID: 36928351
Luvadaxistat modestly improved MMN amplitude (biomarker of auditory processing) at low dose in a small crossover study.
Memory (2)
- Association between increased serum d-serine and cognitive gains induced by intensive cognitive training in schizophrenia
PubMed ID: 29699895
Ī serum Dāserine correlated with verbal learning and memory gains during auditory training (supportive association).
- Behavioral and cognitive effects of the N-methyl-D-aspartate receptor co-agonist D-serine in healthy humans: initial findings
PubMed ID: 25554623
Acute Dāserine improved RAVLT resistance to interference (verbal memory) in healthy adults (direct memory benefit).
Focus & concentration (2)
- A single administration of 'microbial' D-alanine to healthy volunteers augments reaction to negative emotions: A comparison with D-serine
PubMed ID: 32167001
Dāalanine acutely sped recognition/categorization of emotional faces (direct evidence of faster cognitive processing in emotional tasks).
- Behavioral and cognitive effects of the N-methyl-D-aspartate receptor co-agonist D-serine in healthy humans: initial findings
PubMed ID: 25554623
Acute Dāserine produced clear improvement on CPTāIP (attention/vigilance) in healthy adults (direct attention measure).
Mood balance (2)
- Behavioral and cognitive effects of the N-methyl-D-aspartate receptor co-agonist D-serine in healthy humans: initial findings
PubMed ID: 25554623
Acute Dāserine reduced subjective sadness/anxiety on VAS in healthy adults (direct, shortāterm mood effect).
- A single administration of 'microbial' D-alanine to healthy volunteers augments reaction to negative emotions: A comparison with D-serine
PubMed ID: 32167001
Dāalanine acutely improved speed of recognizing negative emotions (changes in emotional processing that can relate to regulation).
Productivity (1)
- A single administration of 'microbial' D-alanine to healthy volunteers augments reaction to negative emotions: A comparison with D-serine
PubMed ID: 32167001
Single-dose Dāalanine in healthy volunteers produced faster recognition/categorization of negative emotions (direct RT evidence).
Motivation & confidence (1)
- D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial
PubMed ID: 26360284
In clinicalāhighārisk individuals Dāserine produced a large (~36%) reduction in negative symptoms (which include avolition/motivation), supporting improved motivation.
Mental clarity (1)
- Behavioral and cognitive effects of the N-methyl-D-aspartate receptor co-agonist D-serine in healthy humans: initial findings
PubMed ID: 25554623
Acute improvements in attention and verbal memory and reduced negative mood suggest better clarity shortly after dosing.
Similar by evidence
Supplements the same benefits carry qualifying findings for ā a fact about the evidence graph, not a recommendation to swap.
Being studied right now
Recruiting clinical trials registered on ClinicalTrials.gov. A trial in progress has no result yet ā this is what the field is asking, not what it found.